Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:
Last year, a novel combination pill developed by Karuna Therapeutics reduced psychosis and related symptoms experienced by patients with schizophrenia, achieving the main goals of a late-stage clinical trial. This quarter, the company hopes to follow up those positive results with the readout of a second, Phase 3 study.
Genetic medicine is expected to have an eventful year, starting with regulatory submissions for two competing treatments for sickle cell disease. Vertex Pharmaceuticals and its partner CRISPR Therapeutics will be completing an FDA marketing application for their CRISPR-based treatment called exa-cel. Gene therapy maker Bluebird Bio will be doing the same with its treatment called lovo-cel.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect